PA8562001A1 - Brivudina estabilizada en formulaciones topicas - Google Patents

Brivudina estabilizada en formulaciones topicas

Info

Publication number
PA8562001A1
PA8562001A1 PA20028562001A PA8562001A PA8562001A1 PA 8562001 A1 PA8562001 A1 PA 8562001A1 PA 20028562001 A PA20028562001 A PA 20028562001A PA 8562001 A PA8562001 A PA 8562001A PA 8562001 A1 PA8562001 A1 PA 8562001A1
Authority
PA
Panama
Prior art keywords
brivudine
topical formulations
stabilized
photodegradation
avoid
Prior art date
Application number
PA20028562001A
Other languages
English (en)
Inventor
Christian Schnittker
Sigrid Keipert
Karsten Groeger
Reinhard Schmitz
Carlo Alberto Maggi
Stefano Manzini
Ulrike Gehlert
Marc Wihsmann
Bettina Stubinski
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of PA8562001A1 publication Critical patent/PA8562001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Devices For Dispensing Beverages (AREA)
  • Filling Of Jars Or Cans And Processes For Cleaning And Sealing Jars (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACIONES TOPICAS QUE CONTIENEN EL AGENTE VIRUSTATICO BRIVUDINA Y ESTABILIZADORES UTILES PARA EVITAR SU FOTODEGRADACION
PA20028562001A 2001-12-19 2002-12-18 Brivudina estabilizada en formulaciones topicas PA8562001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10162593A DE10162593A1 (de) 2001-12-19 2001-12-19 Stabilisierte topische Brivudin-Formulierungen

Publications (1)

Publication Number Publication Date
PA8562001A1 true PA8562001A1 (es) 2003-07-28

Family

ID=7709921

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028562001A PA8562001A1 (es) 2001-12-19 2002-12-18 Brivudina estabilizada en formulaciones topicas

Country Status (15)

Country Link
US (1) US20040259835A1 (es)
EP (1) EP1463513B1 (es)
JP (1) JP2005516929A (es)
CN (1) CN1316977C (es)
AR (1) AR038455A1 (es)
AU (1) AU2002366273A1 (es)
CA (1) CA2470629A1 (es)
DE (2) DE10162593A1 (es)
ES (1) ES2280625T3 (es)
PA (1) PA8562001A1 (es)
PE (1) PE20030696A1 (es)
PL (1) PL369581A1 (es)
RU (1) RU2306935C2 (es)
UY (1) UY27591A1 (es)
WO (1) WO2003051375A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
US8461214B2 (en) * 2004-01-06 2013-06-11 Shiseido Co., Ltd. One-phase microemulsion compositions, O/W ultrafine emulsion external formulations and method for producing the same
DE102005046769A1 (de) * 2005-09-29 2007-04-05 Berlin-Chemie Ag Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
JP5365777B2 (ja) * 2006-09-15 2013-12-11 アステラス製薬株式会社 光に対して安定なラモセトロンの固形医薬組成物
US20100323998A1 (en) * 2007-08-06 2010-12-23 Glenmark Pharmaceuticals Ltd. Topical composition containing the combination of mupirocin and beclomethasone
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2421496A4 (en) * 2009-04-22 2014-01-15 Agency Science Tech & Res EMULSIONS FOR TRANSDERMAL ADMINISTRATION
WO2011039780A2 (en) * 2009-09-22 2011-04-07 Vlife Sciences Technologies Pvt. Ltd. Topical formulation for diabetic foot ulcers
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US8835643B2 (en) 2012-02-23 2014-09-16 Empire Technology Development Llc Molecules, compositions, and methods for light absorption
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
CN106138018B (zh) * 2015-04-02 2020-03-13 广州洁成生物科技有限公司 羟基二苯甲酮在制备抗病毒和抗肿瘤药物中的应用
MX378121B (es) * 2016-08-31 2025-03-10 Oterra As Composición colorante dispersable en agua.
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136282A1 (de) * 1981-09-12 1983-03-24 Hoechst Ag "verfahren zur stabilisierung photoinstabiler arzneistoffe sowie stabilisierte arzneizubereitungen"
FR2737118B1 (fr) * 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
RU2133120C1 (ru) * 1995-12-14 1999-07-20 Сантр Энтернасьональ де Решерш Дерматоложик Галдерма Косметическая или дерматологическая композиция типа эмульсии вода-в-масле
CZ284920B6 (cs) * 1996-02-14 1999-04-14 Vladimír Prof. Mudr. Drsc. Vonka Preparáty pro léčbu rekurentního herpesu založené na potenciaci účinků syntetických virostatik kofeinem
GB9618974D0 (en) * 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
DE19956601A1 (de) * 1999-11-25 2001-05-31 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
AR038455A1 (es) 2005-01-19
UY27591A1 (es) 2003-02-28
CN1316977C (zh) 2007-05-23
ES2280625T3 (es) 2007-09-16
CA2470629A1 (en) 2003-06-26
RU2306935C2 (ru) 2007-09-27
AU2002366273A1 (en) 2003-06-30
JP2005516929A (ja) 2005-06-09
EP1463513B1 (en) 2007-02-21
DE10162593A1 (de) 2003-07-03
PL369581A1 (en) 2005-05-02
US20040259835A1 (en) 2004-12-23
WO2003051375A1 (en) 2003-06-26
DE60218346D1 (de) 2007-04-05
EP1463513A1 (en) 2004-10-06
CN1604782A (zh) 2005-04-06
RU2004118426A (ru) 2005-04-20
DE60218346T2 (de) 2007-11-08
PE20030696A1 (es) 2003-09-22

Similar Documents

Publication Publication Date Title
BR0211390A (pt) Tratamento de infecções da unha com no
BRPI0515316A (pt) compostos de imidazoquinolina
AR028027A1 (es) Componente de compuestos en secciones y procedimiento para producir el mismo
ES2163187T3 (es) Composiciones lavantes y acondicionantes a base de silicona y de dialquileter.
GT200200114A (es) Champues con alcohol de behenilo
DE60310542D1 (de) Kühlende zusammensetzungen und deren verwendungen
NO20033100D0 (no) Uorganiske matrikssammensetninger og kompositter som inneholder matrikssammensetningen
BRPI0316616B8 (pt) emplastro térmico com efeito térmico suficiente que torna a sensação agradável mais duradoura e irritação residual mais reduzida
ES2172747T3 (es) Cateter con ala de fijacion.
DK1409034T3 (da) Topisk farmaceutisk formulering
BR0106913B1 (pt) composições transparentes de limpeza em barra que são eficazes e não são irritantes para os olhos
NO20022989D0 (no) Middel som er anti-adhesivt i forhold til den patogene flora i huden
AR026490A1 (es) Composiciones cosmeticas que contienen extracto de garbanzo en combinacion con retinoides y metodo cosmetico de aplicacion de dicha composicion
BR0116972A (pt) Métodos e dispositivos para administração de substâncias na camada intradérmica da pele para absorção sistêmica
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
GT199900129A (es) Formulaciones liquidas de pirimetanilo y metodos para su preparacion.
CO5611210A2 (es) Composicion de jabon
BR0215913A (pt) Composição de radiofármacos rotulados com 18-f e processo para obtê-los
BRPI0510938A (pt) vitamina k1 como energizador em formulações cosméticas
AU2003299529A8 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
BR0307696A (pt) Composição desodorante ou antitranspirante
ATE387204T1 (de) Zusammensetzung mit induzierendem kathartischen effekt
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
BR0101258B1 (pt) Produto tipo granola e método para fazer o mesmo
AR028411A1 (es) Secuencias de nuclentidos relacionadas con el aumento o la disminucion del endice de ovulacion en mameferos